These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 7588899)

  • 21. Tedisamil and dofetilide-induced torsades de pointes, rate and potassium dependence.
    Barrett TD; Hennan JK; Fischbach PS; O'Neill BP; Driscoll EM; Lucchesi BR
    Br J Pharmacol; 2001 Apr; 132(7):1493-500. PubMed ID: 11264243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experimental models of torsades de pointes.
    Weissenburger J; Davy JM; Chézalviel F
    Fundam Clin Pharmacol; 1993; 7(1):29-38. PubMed ID: 8458600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suppression of torsades de pointes by atropine.
    Tan HL; Wilde AA; Peters RJ
    Heart; 1998 Jan; 79(1):99-100. PubMed ID: 9505930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medical toxicologists' practice patterns regarding drug-induced QT prolongation in overdose patients: a survey in the United States of America, Europe, and Asia Pacific region.
    Othong R; Devlin JJ; Kazzi ZN
    Clin Toxicol (Phila); 2015 May; 53(4):204-9. PubMed ID: 25706450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amiodarone and torsades de pointes in patients with advanced heart failure.
    Middlekauff HR; Stevenson WG; Saxon LA; Stevenson LW
    Am J Cardiol; 1995 Sep; 76(7):499-502. PubMed ID: 7653452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Torsades de pointes ventricular tachycardia induced by intravenous amiodarone].
    Makai A; Rudas L; Liszkai G; Fazekas T
    Orv Hetil; 2003 Feb; 144(5):241-7. PubMed ID: 12647553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Repolarization characteristics and incidence of Torsades de Pointes in patients with acquired complete atrioventricular block.
    Bozkaya YT; Eroğlu Z; Kayikçioğlu M; Payzin S; Can LH; Kültürsay H; Hasdemir C
    Anadolu Kardiyol Derg; 2007 Jul; 7 Suppl 1():98-100. PubMed ID: 17584695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy.
    Keivanidou A; Arnaoutoglou C; Krommydas A; Papanikolaou G; Tsiptses K; Chrisopoulos C; Kirpizidis C
    Cardiol J; 2009; 16(2):172-4. PubMed ID: 19387967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiarrhythmic drugs and torsade de pointes.
    Lazzara R
    Eur Heart J; 1993 Nov; 14 Suppl H():88-92. PubMed ID: 8293758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Amiodarone-induced torsade de pointes--five case reports].
    Kukla P; Słowiak-Lewińska T
    Kardiol Pol; 2004 Apr; 60(4):365-70; discussion 371. PubMed ID: 15226788
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Torsades de Pointes after Ondansetron Infusion in 2 Patients.
    Lee DY; Trinh T; Roy SK
    Tex Heart Inst J; 2017 Oct; 44(5):366-369. PubMed ID: 29259513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Electrocardiographic Predictors of Torsadogenic Risk During Dofetilide or Sotalol Initiation: Utility of a Novel T Wave Analysis Program.
    Sugrue A; Kremen V; Qiang B; Sheldon SH; DeSimone CV; Sapir Y; Striemer BL; Brady P; Asirvatham SJ; Ackerman MJ; Friedman P; Noseworthy PA
    Cardiovasc Drugs Ther; 2015; 29(5):433-41. PubMed ID: 26411977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations.
    Carlsson L; Abrahamsson C; Andersson B; Duker G; Schiller-Linhardt G
    Cardiovasc Res; 1993 Dec; 27(12):2186-93. PubMed ID: 8313427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
    Lentini S; Rao ML; Schröder R; Lüderitz B; Bauriedel G
    Dtsch Med Wochenschr; 2001 Dec; 126(49):1396-400. PubMed ID: 11740632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular drugs inducing QT prolongation: facts and evidence.
    Taira CA; Opezzo JA; Mayer MA; Höcht C
    Curr Drug Saf; 2010 Jan; 5(1):65-72. PubMed ID: 20210721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Probable case of torsades de pointes induced by fluconazole.
    Khazan M; Mathis AS
    Pharmacotherapy; 2002 Dec; 22(12):1632-7. PubMed ID: 12495173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Torsades de pointes with Almokalant, a new class III antiarrhythmic drug.
    Wiesfeld AC; Crijns HJ; Bergstrand RH; Almgren O; Hillege HL; Lie KI
    Am Heart J; 1993 Oct; 126(4):1008-11. PubMed ID: 8213422
    [No Abstract]   [Full Text] [Related]  

  • 38. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.
    Arbel Y; Swartzon M; Justo D
    Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Giant T-U waves precede torsades de pointes in long QT syndrome: a systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation.
    Kirchhof P; Franz MR; Bardai A; Wilde AM
    J Am Coll Cardiol; 2009 Jul; 54(2):143-9. PubMed ID: 19573731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine.
    Lin JC; Quasny HA
    Pharmacotherapy; 1997; 17(3):626-30. PubMed ID: 9165570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.